The latest price target for Astria Therapeutics (NASDAQ:ATXS) was reported by HC Wainwright & Co. on January 23, 2025. The analyst firm set a price target for $16.00 expecting ATXS to rise to within 12 months (a possible 111.92% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Astria Therapeutics (NASDAQ:ATXS) was provided by HC Wainwright & Co., and Astria Therapeutics reiterated their buy rating.

There is no last upgrade for Astria Therapeutics

There is no last downgrade for Astria Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on January 23, 2025 so you should expect the next rating to be made available sometime around January 23, 2026.

While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a reiterated with a price target of $16.00 to $16.00. The current price Astria Therapeutics (ATXS) is trading at is $7.55, which is out of the analyst’s predicted range.